Patents by Inventor Heddy Zola

Heddy Zola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Proteins that bind PI16 and uses thereof
    Patent number: 9605079
    Abstract: The present disclosure provides an isolated protein comprising at least one antibody variable region that is capable of binding to peptidase inhibitor 16 (PI16), wherein the protein is also capable of competitively inhibiting binding of an antibody produced by a hybridoma designated CRCBT-02-001 deposited with the ATCC under Accession Number PTA-10685 to PI16. The present invention also provides use of the protein, e.g., in diagnosis, therapy or to isolate cells, preferably Treg cells.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: March 28, 2017
    Assignee: MEDVET SCIENCE PTY LTD.
    Inventors: Simon Barry, Doreen Krumbiegel, Nicola Ga-Ling Eastaff-Leung, Ian Cameron Nicholson, Heddy Zola
  • BIOMARKERS AND USES THEREOF
    Publication number: 20160320388
    Abstract: The present invention provides markers of regulatory T (Treg) cells, preferably, cell surface markers of Treg cells and uses of those markers or compounds that bind thereto to identify or isolate Treg cells or to diagnose/prognose/treat/prevent Treg-mediated conditions. The present invention also provides methods for identification and/or isolation of Treg cell subpopulations and such isolated subpopulations of Treg cells.
    Type: Application
    Filed: June 13, 2016
    Publication date: November 3, 2016
    Inventors: Simon Barry, Timothy John Sadlon, Stephen Martin Pederson, Bridget Gabrielle Wilkinson, Doreen Krumbiegel, Ian Cameron Nicholson, Heddy Zola
  • PROTEINS THAT BIND PI16 AND USES THEREOF
    Publication number: 20130171153
    Abstract: The present disclosure provides an isolated protein comprising at least one antibody variable region that is capable of binding to peptidase inhibitor 16 (PI16), wherein the protein is also capable of competitively inhibiting binding of an antibody produced by a hybridoma designated CRCBT-02-001 deposited with the ATCC under Accession Number PTA-10685 to PI16. The present invention also provides use of the protein, e.g., in diagnosis, therapy or to isolate cells, preferably Treg cells.
    Type: Application
    Filed: April 18, 2011
    Publication date: July 4, 2013
    Applicant: TransBio Ltd.
    Inventors: Simon Barry, Doreen Krumbiegel, Nicola Ga-Ling Eastaff-Leung, Ian Cameron Nicholson, Heddy Zola
  • BIOMARKERS AND USES THEREOF
    Publication number: 20120064100
    Abstract: The present invention provides markers of regulatory T (Treg) cells, preferably, cell surface markers of Treg cells and uses of those markers or compounds that bind thereto to identify or isolate Treg cells or to diagnose/prognose/treat/prevent Treg-mediated conditions. The present invention also provides methods for identification and/or isolation of Treg cell subpopulations and such isolated subpopulations of Treg cells.
    Type: Application
    Filed: March 18, 2010
    Publication date: March 15, 2012
    Inventors: Simon Barry, Timothy John Sadlon, Stephen Martin Pederson, Bridget Gabrielle Wilkinson, Doreen Krumbiegel, Ian Cameron Nicholson, Heddy Zola
  • Agents and methods for treatment and diagnosis of ocular disorders
    Patent number: 6773916
    Abstract: A method of treating an ocular disorder is disclosed, comprising administering to a patient in need of such treatment, an effective amount of a sub-immunoglobulin antigen-binding molecule that is immuno-interactive with a target antigen associated with the disorder. The invention is also directed to compositions comprising this sub-immunoglobulin antigen-binding molecule and to a method of diagnosing an ocular condition using such molecule.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: August 10, 2004
    Assignee: The Flinders University of South Australia
    Inventors: Michael Alexander Thiel, Heddy Zola, Douglas John Coster, Keryn Anne Williams
  • Preparation of immunosuppressive materials
    Patent number: 4009257
    Abstract: A soluble immunogenic extract of human blood lymphocytes, a non-toxic immunosuppressive antilymphocytic serum raised by the extract, a non-toxic immunosuppressive antilymphocytic immunoglobulin G derived from the serum, and methods of isolating the extract, raising the antiserum and isolating the immunoglobulin G.
    Type: Grant
    Filed: February 24, 1971
    Date of Patent: February 22, 1977
    Assignee: Burroughs Wellcome, Inc.
    Inventors: Derek Thomas, Heddy Zola